BRAF and melanoma: A perioperative combination of encorafenib plus binimetinib will be compared to standard adjuvant therapy in the phase II PREMIUM trial in BRAF V600E mutant patients in stage III (B/C/D) or oligometastatic resectable stage IV melanoma (NCT05097378).